{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T06:30:15Z","timestamp":1764657015244,"version":"3.46.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Pancreatic Acinar Cell Carcinoma (PACC) is a rare subtype of pancreatic cancer, and its systematic treatment protocol is still pending for further exploration. There have been a few reports that PACC patients benefited from immunotherapy-integrated treatment. Here, we present a metastatic PACC patient who had new hepatic lesions but lowered serum AFP and CA19\u20139 after 2 cycles of integrated treatment that included chemotherapy, PD-1 blockade and antiangiogenic therapy, which was later confirmed to be pseudoprogression (PsP) by pathological diagnosis. So far as we know, this is the first reported PsP case of PACC. This case highlighted the value of biopsy in distinguishing PsP from authentic tumor progression of PACC.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1663514","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T06:26:37Z","timestamp":1764656797000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Pseudoprogression of pancreatic acinar cell carcinoma after PD-1 blockade integrated treatment"],"prefix":"10.3389","volume":"16","author":[{"given":"Xinyuan","family":"Bai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaru","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haochen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baorui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huizi","family":"Sha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1038\/modpathol.3800686","article-title":"Nonductal neoplasms of the pancreas","author":"Klimstra","year":"2007","journal-title":"Mod Pathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v28.i40.5827","article-title":"Pancreatic acinar cell carcinoma: A comprehensive review","volume":"28","author":"Calimano-Ramirez","year":"2022","journal-title":"World J Gastroenterol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.02.005","article-title":"Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors","volume":"20","author":"Holen","year":"2002","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-16331-4","article-title":"Survival outcomes and genetic characteristics of resected pancreatic acinar cell carcinoma","volume":"32","author":"Blair","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.692480","article-title":"Rapid response to the combination of lenvatinib and sintilimab in a pancreatic acinar cell carcinoma patient with elevated alpha-fetoprotein: A case report","volume":"11","author":"Qin","year":"2021","journal-title":"Front Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1210064","article-title":"New treatment insights into pancreatic acinar cell carcinoma: case report and literature review","volume":"13","author":"Zhao","year":"2023","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1357233","article-title":"Case report: Immunotherapy in rare high TMB pancreatic acinar carcinoma","volume":"14","author":"Wu","year":"2024","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment","volume":"18","author":"Yi","year":"2019","journal-title":"Mol Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2019.0144","article-title":"The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy","volume":"16","author":"Jia","year":"2019","journal-title":"Cancer Biol Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-020-00425-y","article-title":"Pseudoprogression and hyperprogression as new forms of response to immunotherapy","volume":"34","author":"Frelaut","year":"2020","journal-title":"BioDrugs"},{"key":"B12","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/cncr.32522","article-title":"Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy","volume":"126","author":"Pires da Silva","year":"2020","journal-title":"Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-020-07249-y","article-title":"Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial","volume":"31","author":"Ahmed","year":"2021","journal-title":"Eur Radiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/bjc.2017.145","article-title":"A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)","volume":"117","author":"Weiss","year":"2017","journal-title":"Br J Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"103531","DOI":"10.1016\/j.critrevonc.2021.103531","article-title":"Pseudoprogression in lung cancer patients treated with immunotherapy","volume":"169","author":"Chen","year":"2022","journal-title":"Crit Rev oncology\/hematology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0020","article-title":"Radiomics, tumor volume, and blood biomarkers for early prediction of pseudoprogression in patients with metastatic melanoma treated with immune checkpoint inhibition","volume":"26","author":"Basler","year":"2020","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx190","article-title":"Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients","volume":"28","author":"Sanmamed","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1227\/neu.0000000000001982","article-title":"Circulating tumor DNA in adults with glioma: A systematic review and meta-analysis of biomarker performance","volume":"91","author":"Mcmahon","year":"2022","journal-title":"Neurosurgery"},{"key":"B20","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41568-024-00674-x","article-title":"Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity","volume":"24","author":"Meier","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.56.5.559","article-title":"Essential involvement of interleukin-8 (IL-8) in acute inflammation","volume":"56","author":"Harada","year":"1994","journal-title":"J leukocyte Biol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12885-023-10661-4","article-title":"Sintilimab Plus Apatinib and Chemotherapy as Second\u2212\/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial","volume":"23","author":"Zhang","year":"2023","journal-title":"BMC Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41392-025-02193-z","article-title":"PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trial","volume":"10","author":"Wang","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41392-024-01788-2","article-title":"XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial","volume":"9","author":"Pan","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00529","article-title":"Atezolizumab combined with bevacizumab and platinum-based therapy for platinum-sensitive ovarian cancer: placebo-controlled randomized phase III ATALANTE\/ENGOT-ov29 trial","volume":"41","author":"Kurtz","year":"2023","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2024.02.003","article-title":"Targeting PKM2 signaling cascade with salvianic acid A normalizes tumor blood vessels to facilitate chemotherapeutic drug delivery","volume":"14","author":"Qian","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2017.06.035","article-title":"Tumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery","volume":"403","author":"Kim","year":"2017","journal-title":"Cancer Lett"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nature21724","article-title":"Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming","volume":"544","author":"Tian","year":"2017","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-021-01102-5","article-title":"The relationship between expression of PD-L1 and HIF-1\u03b1 in glioma cells under hypoxia","volume":"14","author":"Ding","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-017-9562-9","article-title":"Tumor angiogenesis and vascular normalization: alternative therapeutic targets","volume":"20","author":"Viallard","year":"2017","journal-title":"Angiogenesis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.cbi.2014.12.030","article-title":"STAT3-dependent VEGF production from keratinocytes abrogates dendritic cell activation and migration by arsenic: a plausible regional mechanism of immunosuppression in arsenical cancers","volume":"227","author":"Hong","year":"2015","journal-title":"Chemico-biological Interact"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J Exp Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32023","article-title":"Immunomodulatory effects of lenvatinib plus anti-programmed cell death protein 1 in mice and rationale for patient enrichment in hepatocellular carcinoma","volume":"74","author":"Torrens","year":"2021","journal-title":"Hepatol (Baltimore Md)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1663514\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T06:26:39Z","timestamp":1764656799000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1663514\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2025.1663514"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1663514","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"article-number":"1663514"}}